Zobrazeno 1 - 10
of 2 003
pro vyhledávání: '"Graft versus leukemia"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Although allogeneic hematopoietic cell transplantation (HCT) represents a curative approach for many patients with hematological diseases, post-transplantation relapse occurs in 20-50% of cases, representing the primary cause of treatment failure and
Externí odkaz:
https://doaj.org/article/ad6aed26b47246a19c50bfae3518e995
Autor:
Ashley D. Hadjis, Shannon R. McCurdy
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Allogeneic hematopoietic cell transplantation (HCT) has transformed over the past several decades through enhanced supportive care, reduced intensity conditioning (RIC), improved human leukocyte antigen (HLA) typing, and novel graft-versus-host disea
Externí odkaz:
https://doaj.org/article/e107391e9f654cecbd464890851c5fcd
Autor:
Stefania Braidotti, Marilena Granzotto, Debora Curci, Barbara Faganel Kotnik, Natalia Maximova
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1853 (2024)
Optimized use of prophylactic or therapeutic donor lymphocyte infusions (DLI) is aimed at improving clinical outcomes in patients with malignant and non-malignant hematological diseases who have undergone allogeneic hematopoietic stem cell transplant
Externí odkaz:
https://doaj.org/article/e724ab7d952543bc85fe38b663375f3e
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is the only curative therapy for many hematologic malignancies, whereby the Graft-versus-Leukemia (GVL) effect plays a pivotal role in controlling relapse. However, the success of GVL is
Externí odkaz:
https://doaj.org/article/f67351aa2b0d4ae19636d217e68c9bb7
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Acute Myeloid Leukemia (AML) is the prototype of cancer genomics as it was the first published cancer genome. Large-scale next generation/massively parallel sequencing efforts have identified recurrent alterations that inform prognosis and have guide
Externí odkaz:
https://doaj.org/article/c5773205d2b34e849143efd3046e4eb1
Autor:
Katie Maurer, Joseph H. Antin
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for many hematologic malignancies as well as non-malignant conditions. Part of the curative basis underlying HSCT for hematologic malignancies relies upon ind
Externí odkaz:
https://doaj.org/article/76ab829b39e94e9b922ff43535853bda
Autor:
Ann-Cathrin Burk, Petya Apostolova
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed to cure hematological malignancies, such as acute myeloid leukemia (AML), through the graft-versus-leukemia (GVL) effect. In this immunological process, donor immune cel
Externí odkaz:
https://doaj.org/article/20a0547f98954333b59260530802327a
Autor:
Yili Fan, Luyao Wang, Boxiao Chen, Jiawei Zhang, Luyu Yang, Xi Qiu, Huawei Jiang, Lei Zhu, Chao Wang, Yang Xu
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
For patients with primary refractory AML, allogeneic hematopoietic cell transplantation (allo-HCT) is considered the only curative approach. However, the therapeutic efficacy of salvage transplantation in the non-remission (NR) state remains controve
Externí odkaz:
https://doaj.org/article/1e10298fe1024619981013fa668c5cb0
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundMesenchymal stem cells (MSCs) can alleviate graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation (HSCT). MSCs-derived exosomes (MEXs) can mirror the biological function of their parent cells. Whether MEXs can alleviat
Externí odkaz:
https://doaj.org/article/baa53864a4bd43e7bbdc9fe84f1a2761
Autor:
Takanori Teshima, Daigo Hashimoto
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for various hematologic malignancies. However, alloimmune response is a double-edged sword that mediates both beneficial graft-versus-leukemia (GVL) effects and harmful graft-v
Externí odkaz:
https://doaj.org/article/32decd913a8c492d907164c187854ab4